NASDAQ:RUBY - Rubius Therapeutics Stock Price, News, Headlines & Rumors

Sign in or create an account to add this stock to your watchlist.
$22.32 -0.94 (-4.04 %)
(As of 08/14/2018 04:00 PM ET)
Previous Close$23.26
Today's Range$21.56 - $24.10
52-Week Range$19.78 - $33.01
Volume141,887 shs
Average Volume340,605 shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rubius Therapeutics logoThere is no company description available for Rubius Therapeutics Inc.

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RUBY
CUSIPN/A
Phone617-679-9600

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees83
Outstanding Shares77,330,000
Market Cap$1.84 billion

Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

What price target have analysts set for RUBY?

4 Wall Street analysts have issued 12-month price targets for Rubius Therapeutics' stock. Their forecasts range from $37.00 to $40.00. On average, they expect Rubius Therapeutics' share price to reach $38.50 in the next year. This suggests a possible upside of 72.5% from the stock's current price. View Analyst Price Targets for Rubius Therapeutics.

What is the consensus analysts' recommendation for Rubius Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rubius Therapeutics.

Who are some of Rubius Therapeutics' key competitors?

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an IPO on Wednesday, July 18th 2018. The company issued 9,500,000 shares at a price of $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners acted as the underwriters for the IPO.

When does the company's quiet period expire?

Rubius Therapeutics' quiet period expires on Monday, August 27th. Rubius Therapeutics had issued 10,483,000 shares in its IPO on July 18th. The total size of the offering was $241,109,000 based on an initial share price of $23.00. During the company's quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Has Rubius Therapeutics been receiving favorable news coverage?

Press coverage about RUBY stock has been trending somewhat positive on Tuesday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Rubius Therapeutics earned a news impact score of 0.22 on Accern's scale. They also gave media stories about the company an impact score of 45.90 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days. View Recent Headlines for Rubius Therapeutics.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $22.32.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $1.84 billion. Rubius Therapeutics employs 83 workers across the globe.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 325 VASSAR STREET SUITE 1A, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]


MarketBeat Community Rating for Rubius Therapeutics (NASDAQ RUBY)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  10 (Vote Outperform)
Underperform Votes:  7 (Vote Underperform)
Total Votes:  17
MarketBeat's community ratings are surveys of what our community members think about Rubius Therapeutics and other stocks. Vote "Outperform" if you believe RUBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RUBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/14/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.